论文部分内容阅读
他1934年出生于辽宁沈阳,1956年毕业于北京医科大学。他做了近20年的儿科临床医生,却中途转行从事中药药理研究,出身西医,却献身中医,始于临床,却归于基础。他参与主持的“血瘀证及活血化瘀研究”和“双龙方与自体骨髓干细胞经心导管移植治疗冠心病的研究”分别获2003年度国家科技进步一等奖、中华中医药学会科技进步一等奖;他自主或合作研制了冠心Ⅱ号等70种新药(其中活血化瘀新药30种),为继承发扬中医药学、推动中西医结合及中医药现代化起到带头作用;他创立了我国中药药效学评价标准及技术规范。他就是我国著名中药药理专家、中国工程院院士李连达。
He was born in Shenyang, Liaoning Province in 1934 and graduated from Beijing Medical University in 1956. He has done nearly 20 years of pediatric clinicians, but switched to traditional Chinese medicine pharmacology research, was born in Western medicine, but devoted themselves to Chinese medicine, began in clinical, but attributed to the foundation. He participated in the “study of blood stasis and blood circulation” and “Ssangyong and autologous bone marrow stem cell transplantation in the treatment of coronary heart disease research” respectively by the 2003 National Science and Technology Progress Award, the Chinese Academy of Medical Sciences, a scientific and technological progress Etc. He autonomously or cooperatively developed 70 new drugs (including 30 kinds of new drugs for promoting blood circulation and removing blood circulation), such as Guanxin II. He took the lead in inheriting and developing Chinese medicine and promoting the integration of traditional Chinese and western medicine and the modernization of Chinese medicine. He founded China Pharmacodynamic evaluation criteria and technical specifications of Chinese medicine. He is China’s famous Chinese medicine pharmacology expert, Chinese Academy of Engineering Li Lian Da.